Vitura Health (ASX:VIT) has released its financial results for the half-year ended Dec. 31, 2025, revealing a period of revenue growth tempered by sector-wide margin pressures.
The Melbourne-based digital health firm reported total revenue of $67.9 million, representing an 8.3% increase over the previous corresponding period.
The growth was bolstered by a strong performance from the Doctors on Demand telehealth business, which saw a 21% revenue hike, and Nicotine Vaping Product sales, which exceeded forecasts with a 16% average growth rate.
Normalised EBITDA fell to $1.9 million from $4.6 million in the prior year, while normalised loss after income tax reached $0.4 million.
Management attributed this downturn to increased doctor costs and a sector-wide compression in medicinal cannabis pricing.
In response, Vitura has initiated a management restructure and a leadership transition aimed at accelerating execution.
The company reduced operational expenditure by 10%, achieving annualised savings of $2.8 million.
Strategic integration also remains a priority; CDA Clinics and Cannadoc have been migrated to a unified platform under the new "Specialty Clinics" division.
At the time of reporting, Vitura Health's share price was $0.046.